<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04914273</url>
  </required_header>
  <id_info>
    <org_study_id>21-15 EXPLORE</org_study_id>
    <nct_id>NCT04914273</nct_id>
  </id_info>
  <brief_title>Use of Exhaled Particles to Assess Lung Pharmacokinetics</brief_title>
  <acronym>EXPLORE</acronym>
  <official_title>Exhaled Particles in Lung Pharmacokinetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fraunhofer-Institute of Toxicology and Experimental Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fraunhofer-Institute of Toxicology and Experimental Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research project in humans aims at increasing the general understanding of lung&#xD;
      pharmakokinetic by sampling exhaled particles. The central hypothesis of this study is that&#xD;
      pharmacokinetics of Salbutamol (model drug) can be monitored in exhaled particles.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the present study is to increase the general understanding of lung pharmakokinetic&#xD;
      by systematically sampling exhaled particles at pre-specified quantities to reproduce and&#xD;
      extent existing pilot data. For comparison, samples of blood plasma and nasal filter samples&#xD;
      (nasosorption) will be collected for pharmakokinetic analyzes. Nasosorption will be performed&#xD;
      to explore the possibility of detecting drug concentrations in nasal filter paper samples.&#xD;
&#xD;
      Salbutamol will be administered by inhalation and orally in a cross-over study design and&#xD;
      both application routes shall be comparised regarding the detection of pharmakokinetic data.&#xD;
      The aim of the study is not to generate safety or efficacy data of the selected licensed&#xD;
      drugs. The choice of drugs is based on general considerations regarding therapy of airway&#xD;
      diseases and the physical-chemical properties of the compounds. It is not driven by the&#xD;
      compounds per se.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 14, 2021</start_date>
  <completion_date type="Actual">August 3, 2021</completion_date>
  <primary_completion_date type="Actual">August 3, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Salbutamol concentration assessed in exhaled particles over 5 hours after inhaled versus oral administration</measure>
    <time_frame>Before, 0 min, 20 min, 40 min, 60 min, 120 min, 180 min, 240 min, 270 min, 300 min after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Salbutamol concentration assessed in blood plasma over 5 hours after inhaled versus oral administration</measure>
    <time_frame>Before, 0 min, 15 min, 35 min, 55 min, 75 min, 135 min, 195 min, 255 min, 285 min, 315 min after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Salbutamol concentration assessed in nasal filter samples (nasosorption) over 5 hours after inhaled versus oral administration</measure>
    <time_frame>Before, 0 min, 15 min, 35 min, 55 min, 75 min, 135 min, 195 min, 255 min, 285 min, 315 min after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of the sampling method by assessing adverse events</measure>
    <time_frame>Day 1 to Day 18</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy</condition>
  <condition>Lung Pharmacokinetic</condition>
  <arm_group>
    <arm_group_label>Sequence A: 1. Ingestion 2. Inhalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A is treated in the following sequence: 1. oral drug 2. inhalative drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence B: 1. Inhalation 2. Ingestion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group B is treated in the following sequence: 1. inhalative drug 2. oral drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhalation Spray</intervention_name>
    <description>400 mcg salbutamol administered per metered dose inhaler</description>
    <arm_group_label>Sequence A: 1. Ingestion 2. Inhalation</arm_group_label>
    <arm_group_label>Sequence B: 1. Inhalation 2. Ingestion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tablet</intervention_name>
    <description>8 mg salbutamol administered per tablet for ingestion</description>
    <arm_group_label>Sequence A: 1. Ingestion 2. Inhalation</arm_group_label>
    <arm_group_label>Sequence B: 1. Inhalation 2. Ingestion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able and willing to give written informed consent.&#xD;
&#xD;
          2. Healthy male and female subjects, aged 18-65 years. Women will be considered for&#xD;
             inclusion if they are:&#xD;
&#xD;
             Not pregnant, as confirmed by pregnancy test (see flow chart), and not nursing. Of&#xD;
             non-child bearing potential (i.e. physiologically incapable of becoming pregnant,&#xD;
             including any female who is pre-menarchial or post-menopausal, with documented proof&#xD;
             of hysterectomy or tubal ligation, or meets clinical criteria for menopause and has&#xD;
             been amenorrhoeic for more than 1 year prior to the screening visit).&#xD;
&#xD;
             Of childbearing potential and using a highly effective method of contraception during&#xD;
             the entire study (vasectomised partner, sexual abstinence - the lifestyle of the&#xD;
             female should be such that there is complete abstinence from intercourse from two&#xD;
             weeks prior to the first dose of study medication until at least 72 hours after&#xD;
             treatment -, implants, injectables, combined oral contraceptives, hormonal IUDs or&#xD;
             double-barrier methods, i.e. any double combination of IUD, condom with spermicidal&#xD;
             gel, diaphragm, sponge, and cervical cap).&#xD;
&#xD;
          3. Body mass index between 18 and 32 kg/m2&#xD;
&#xD;
          4. Normal lung function with FEV1 predicted ≥ 80% and FEV1/FVC ≥ 70% at screening V1 ( or&#xD;
             performed within 12 months prior to the screening visit at Fraunhofer ITEM and no&#xD;
             evidence of clinical relevant abnormal findings in the lung function in the previous&#xD;
             year before screening in the anamnesis).&#xD;
&#xD;
          5. Nonsmokers with a history of less than 1 pack year having been nonsmokers for at least&#xD;
             the last 12 months&#xD;
&#xD;
          6. Emission of acceptable quantities of exhaled particles at screening (&gt;200ng particle&#xD;
             mass within 15 min)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any clinically relevant abnormal findings, which, in the opinion of the investigator,&#xD;
             may either put the subject at risk because of participation in the study or may&#xD;
             influence the results of the study, or the subject's ability to participate in the&#xD;
             study&#xD;
&#xD;
          2. Past or present disease, which as judged by the investigator, may affect the outcome&#xD;
             of this study. These diseases include, but are not limited to, cardiovascular disease,&#xD;
             malignancy, hepatic disease, renal disease, hematological disease, neurological&#xD;
             disease, endocrine disease or pulmonary disease (including but not confined to asthma,&#xD;
             chronic bronchitis, emphysema, tuberculosis, bronchiectasis or cystic fibrosis).&#xD;
&#xD;
          3. Regular intake of any prescribed or over the counter medication. Exceptions include&#xD;
             paracetamol for pain relief, oral contraceptive medication, hormonal replacement&#xD;
             therapy, dietary and vitamin supplements&#xD;
&#xD;
          4. Clinically relevant history of allergy as judged by the investigator&#xD;
&#xD;
          5. Intolerance or contraindications to salbutamol&#xD;
&#xD;
          6. Infections of the lower respiratory tract within 4 weeks before visit 1, visit 2 or&#xD;
             visit 3. These patients can be rescreened starting from visit 1.&#xD;
&#xD;
          7. Participation in another clinical trial with an IMP 30 days or five half-lives,&#xD;
             whichever is longer, prior to enrollment&#xD;
&#xD;
          8. History of drug or alcohol abuse&#xD;
&#xD;
          9. Risk of non-compliance with study procedures&#xD;
&#xD;
         10. Suspected inability to understand the protocol requirements, instructions and&#xD;
             study-related restrictions, the nature, scope, and possible consequences of the study&#xD;
&#xD;
         11. Significant nasal deformity, recent nasal surgery or obstructing nasal polyps&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fraunhofer Institute for Toxicology and Experimental Medicine</name>
      <address>
        <city>Hannover</city>
        <state>Lower Saxony</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Schwarz K, Biller H, Windt H, Koch W, Hohlfeld JM. Characterization of exhaled particles from the healthy human lung--a systematic analysis in relation to pulmonary function variables. J Aerosol Med Pulm Drug Deliv. 2010 Dec;23(6):371-9. doi: 10.1089/jamp.2009.0809. Epub 2010 May 25.</citation>
    <PMID>20500095</PMID>
  </reference>
  <reference>
    <citation>Schwarz K, Biller H, Windt H, Koch W, Hohlfeld JM. Characterization of exhaled particles from the human lungs in airway obstruction. J Aerosol Med Pulm Drug Deliv. 2015 Feb;28(1):52-8. doi: 10.1089/jamp.2013.1104. Epub 2014 Jun 10.</citation>
    <PMID>24914577</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 31, 2021</study_first_submitted>
  <study_first_submitted_qc>May 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2021</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fraunhofer-Institute of Toxicology and Experimental Medicine</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Jens Hohlfeld</investigator_full_name>
    <investigator_title>Prof. Dr. Jens M Hohlfeld</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

